The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Strategic 1-multi-line therapy trial in unresectable wild-type RAS metastatic colorectal cancer : A gercor randomized open-label phase III study.
Benoist Chibaudel
Consultant or Advisory Role - Roche
Christophe Tournigand
No relevant relationships to disclose
Franck Bonnetain
Honoraria - Bristol-Myers Squibb; Merck; Roche
Research Funding - Roche
Marine Hug de larauze
No relevant relationships to disclose
Armand De Gramont
No relevant relationships to disclose
Pierre Laurent-Puig
Consultant or Advisory Role - Amgen; IntegraGen; Merck Serono
Christophe Louvet
Honoraria - Merck; Roche/Genentech
Thierry André
Consultant or Advisory Role - Amgen; Merck; Roche
Honoraria - Amgen; Merck; Roche
Aimery De Gramont
Consultant or Advisory Role - Roche
Honoraria - Roche